Core Insights - Oruka Therapeutics has initiated the EVERLAST-A Phase 2a trial for ORKA-001, with data expected in the second half of 2026 [1][6] - The company aims to establish ORKA-001 as a leading treatment for chronic skin diseases, particularly plaque psoriasis, by demonstrating its unique dosing interval and efficacy [2][14] Company Updates - ORKA-001 is a novel half-life extended IL-23p19 monoclonal antibody, while ORKA-002 is a half-life extended IL-17A/F monoclonal antibody currently in Phase 1 trials [3][4] - The EVERLAST-A trial is designed to enroll approximately 80 patients with moderate-to-severe plaque psoriasis, focusing on achieving complete skin clearance [6] - The company has completed dosing for all 24 subjects in the Phase 1 trial of ORKA-001, with results to be presented at the EADV Congress in September 2025 [6] Financial Performance - As of June 30, 2025, Oruka had cash, cash equivalents, and marketable securities totaling $351.5 million, with a net cash usage of $23.1 million in Q2 2025 [9] - Research and Development (R&D) expenses increased to $24.1 million in Q2 2025 from $18.7 million in Q2 2024, primarily due to employee compensation [10] - General and Administrative (G&A) expenses rose to $4.3 million in Q2 2025 from $2.8 million in Q2 2024, reflecting growth in operations and public company costs [11] Pipeline Developments - ORKA-002's Phase 1 trial is ongoing, with interim data expected around the end of 2025 and a Phase 2 trial planned for the first half of 2026 [4] - The company is also advancing ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001, aimed at providing rapid and deep responses in psoriatic disease treatment [7][8]
Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update